Compare DexCom, Inc. (DXCM) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nasdaq100 ETF — how do they compare? DexCom, Inc. trades at $90.65 (market cap $33.79B), while Nasdaq100 ETF trades at $723.5. The key difference: DexCom, Inc. is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | QQQ | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $746.16 |
52-Week Low | $54.84 | $558.34 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
QQQ trades at $725.07, up 0.59% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro increasing its position by 2,685.7%. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend momentum. The Nasdaq-100 tracker benefits from tech sector strength and AI-driven market leadership.
QQQ's outlook remains positive given tech sector momentum and institutional accumulation. Key risks include concentration in mega-cap tech stocks and potential volatility from Fed policy shifts. The ETF's long-term performance record and current technical setup support continued upside potential, though investors should monitor overbought conditions and sector rotation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
